Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab.
Lin AL, Jonsson P, Tabar V, Yang TJ, Cuaron J, Beal K, Cohen M, Postow M, Rosenblum M, Shia J, DeAngelis LM, Taylor BS, Young RJ, Geer EB.
Lin AL, et al.
J Clin Endocrinol Metab. 2018 Oct 1;103(10):3925-3930. doi: 10.1210/jc.2018-01347.
J Clin Endocrinol Metab. 2018.
PMID: 30085142
Free PMC article.